A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus

GlaxoSmithKline (GSK)

Status and phase

Terminated

Phase 2

Conditions

Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Treatments

Drug: Oral GW677954 Capsules (15 mg)

Drug: Insulin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00437164

ADG106149

Details and patient eligibility

About

Many drugs used for the treatment of Type 2 Diabetes Mellitus cause the body to retain water. This study will assess whether or not GW677954 causes the body to retain fluid.

Enrollment

1 patient

Sex

All

Ages

30 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Have been diagnosed by a doctor with Type 2 Diabetes Mellitus at least 3 months before Screening
Have a body mass index within range 25 to 40.0kg/m2 inclusive
Females who meet above criteria must be physiologically incapable of becoming pregnant (ie., surgically sterilized, or post-menopausal per protocol definition)

Exclusion criteria

Significant weight loss or gain in the 3 months before screening
Have used insulin to treat hyperglycemia within 3 months before screening
Have a history of fluid retention
Have uncontrolled high blood pressure
Have liver disease
Take loop diuretics (water pills), certain blood thinners, and/or St. Johns Wort. - Have or have had certain kinds of cancer